Adicet Bio Inc (ACET)

Adicet Bio's stock price has been volatile, declining 28.2% over the last six months and 45.6% over the past year. In December 2025, Adicet Bio announced a reverse stock split to maintain its Nasdaq listing. In October-November 2025, the company reported promising initial safety and efficacy data from its ADI-001 therapy trial for autoimmune diseases. In August 2025, Adicet Bio reported its second-quarter 2025 financial results and announced strategic cost reductions, including a workforce reduction of approximately 30%. In October 2025, Adicet Bio announced an $80 million stock offering. In January 2026, the company provided a corporate update highlighting expected 2026 milestones.

As a clinical-stage biotechnology company, Adicet Bio, Inc. does not currently generate revenue from commercial product sales, therefore, the concept of "demand seasonality" is not applicable at this stage of the company's development.

Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases. The company's platform engineers "off-the-shelf" gamma delta T cells with CARs to enhance tumor targeting. Its lead product candidate, ADI-001, is in Phase 1 clinical trials for autoimmune diseases and relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. The company plans to submit an investigational new drug application for ADI-212 in the first quarter of 2026.

Adicet Bio, Inc. is headquartered in Boston, Massachusetts, United States. The company has operations in the U.S. and Suzhou, China, where it conducts process development and manufacturing.

Adicet Bio's brand reputation has been influenced by positive clinical advancements and financial restructuring. The positive Phase 1 clinical data for ADI-001 in autoimmune diseases has been a significant positive event. However, the company faces a challenging financial outlook, with projected net losses and a workforce reduction. Analysts generally have a "Moderate Buy" to "Strong Buy" consensus rating for Adicet Bio.

Adicet Bio, Inc. has significant institutional ownership, with 186 institutions holding 45.53% of the total shares. Major institutional shareholders include Orbimed Advisors LLC, Tang Capital Management LLC, and RA Capital Management, L.P. Individual insiders, including CEO Chen Schor, also own company stock.